9.19
Alvotech stock is traded at $9.19, with a volume of 168.91K.
It is down -4.67% in the last 24 hours and down -19.10% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$9.64
Open:
$9.46
24h Volume:
168.91K
Relative Volume:
1.13
Market Cap:
$2.77B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-4.9676
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-20.43%
1M Performance:
-19.10%
6M Performance:
-25.28%
1Y Performance:
-19.39%
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALVO
Alvotech
|
9.19 | 2.77B | 391.87M | -441.45M | -301.21M | -1.85 |
![]()
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Alvotech Stock (ALVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-25 | Initiated | UBS | Buy |
Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
Sep-21-23 | Initiated | Barclays | Equal Weight |
Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat
Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Alvotech Shatters Growth Records: 427% Revenue Surge Signals Major Biosimilar Breakthrough - Stock Titan
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com
Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks
Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener
UK Medicines and Healthcare Products Regulatory - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times
Earnings Scheduled For March 26, 2025 - Benzinga
UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.
Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News
Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada
Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq
Northland reiterates Alvotech stock with $28 target on acquisition - Investing.com India
Icelandic Biotech Company Alvotech to Explore Listing in Stockholm - MarketWatch
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03 - MSN
Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m - insights.citeline.com
Alvotech Expands with Acquisition of Xbrane’s R&D Operations - TipRanks
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):